Personalized and Precision Medicine (PPM) as a Unique Healthcare Model | Sergey

Summary :
⁣A new and upgraded approach to the diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). The latter does need to be drastically and globally re-armed and re-innovated! To achieve the implementation of PPM con-cept, it is necessary to create a fundamentally new strategy based upon the biomarker-guided target-ing and bionavigating to have a unique impact for the implementation of PPM model into the daily Clinical Practice, Biotech and Biopharma. In this sense, despite breakthroughs in research that have led to an increased understanding of PPM-controlled human disease, the translation of discoveries into therapies for patients has not kept pace with medical need. It would be extremely useful to in-tegrate data harvesting from different databanks for applications such as prediction and personali-zation of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones and/or theranostics), preventive and therapeutic (targeted molecular and cellular) etc. Bio-designers, Bioengineers and Biomanufacturers are beginning to realize the promise of PPM, translating to direct benefit to patients or persons-at-risk. For instance, companion diagnostics tools (CDTs), theranostics and targeted therapies represent important stakes for the Biotech & Biopharma, in terms of market access, of return on investment and of image among the prescribers.


About Author :
⁣A new and upgraded approach to the diseased states and wellness resulted in a new trend in the healthSergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doc-tors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor De-gree at the National Institute of Immunology, Russia. From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Re-search Institute (MONIKI). In 1993-1996, Dr Suchkov was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.care services, namely, personalized and precision medicine (PPM). The latter does need to be drastically and globally re-armed and re-innovated! To achieve the implementation of PPM con-cept, it is necessary to create a fundamentally new strategy based upon the biomarker-guided target-ing and bionavigating to have a unique impact for the implementation of PPM model into the daily Clinical Practice, Biotech and Biopharma. In this sense, despite breakthroughs in research that have led to an increased understanding of PPM-controlled human disease, the translation of discoveries into therapies for patients has not kept pace with medical need. It would be extremely useful to in-tegrate data harvesting from different databanks for applications such as prediction and personali-zation of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones and/or theranostics), preventive and therapeutic (targeted molecular and cellular) etc. Bio-designers, Bioengineers and Biomanufacturers are beginning to realize the promise of PPM, translating to direct benefit to patients or persons-at-risk. For instance, companion diagnostics tools (CDTs), theranostics and targeted therapies represent important stakes for the Biotech & Biopharma, in terms of market access, of return on investment and of image among the prescribers.